Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20701229 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1TSHRDPP4IDO1 | |
| SCHEMBL20701235 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1TSHRDPP4IDO1 | |
| SCHEMBL8273946 | 0.84 | GPR119 (0.48) | DPP4NR1H2NR1H3GPR119CCR3 | |
| SCHEMBL13344519 | 0.84 | GPR119 (0.48) | DPP4NR1H2NR1H3GPR119CCR3 | |
| SCHEMBL20701193 | 0.84 | USP30 (0.42) | USP30NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL20701195 | 0.84 | USP30 (0.42) | USP30NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL20701192 | 0.84 | USP30 (0.42) | USP30NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL30075712 | 0.83 | HCRTR2 (0.47) | KDM4ENR1H2NR1H3 | |
| SCHEMBL13344516 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TSHRUSP30OPRK1 | |
| SCHEMBL13369119 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TSHRUSP30OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | disclosed |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-02 | — | — | US | disclosed |
| US-11440883-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-13 | — | — | US | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| CN-111051295-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-10584097-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-10 | — | — | US | disclosed |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-16 | — | — | US | disclosed |
| US-10428023-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040010-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-20200207734-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-11440883-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-10428023-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-10584097-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-20200017444-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
| US-20200207715-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | KDM4E 706/4885ALDH1A1 1384/4885TSHR 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.